Kanghong Pharma announced that a total of 13 key products from the company and its subsidiaries have been included in the National Essential Medicines List, 2026 edition. Among them, four are newly added products: Conbercept Ophthalmic Injection prefilled syringe, Shugan Jieyu Capsules, Eszopiclone Tablets, and Tofacitinib Citrate Extended-Release Tablets. The new list takes effect on September 1, 2026, which will facilitate the promotion and use of these products in medical institutions at all levels, but the impact on current operating performance cannot be accurately estimated at this time.
Chengdu Kanghong Pharmaceuticals Group Co Ltd13 products included in National Essential Medicines List, facilitating promotion and use in medical institutions.